Showing Results for
- Academic Journals (39)
Search Results
- 39
Academic Journals
- 39
- Search Terms:
- 1From: Nature Biotechnology. (Vol. 23, Issue 3) Peer-ReviewedAuthor(s): Monya Baker [1] What drug and diagnostic companies want, more than anything, is the ability to predict the future. Rather than waiting years and studying thousands of patients, they want to be able to tell...
- 2From: Nature Biotechnology. (Vol. 23, Issue 3) Peer-ReviewedDavid B. Goldstein has joined Duke University's Institute for Genome Sciences & Policy (IGSP; Durham, NC, USA). He will direct the new IGSP Center for Population Genomics and Pharmacogenetics, which IGSP director...
- 3From: Nature Biotechnology. (Vol. 23, Issue 3) Peer-ReviewedAuthor(s): Kevin R Coombes (corresponding author) [1]; Jeffrey S Morris [1]; Jianhua Hu [1]; Sarah R Edmonson [2]; Keith A Baggerly [1] During the three years since the US National Cancer Institute-Food and Drug...
- 4From: Nature Biotechnology. (Vol. 23, Issue 3) Peer-ReviewedAuthor(s): Thomas J Hoban [1] The Future of Food Written and directed by Deborah Koons Garcia Lily Films, 2004 89 minutes , $20 Genetically modified (GM) crops have fallen far short of early expectations in...
- 5From: Nature Biotechnology. (Vol. 23, Issue 3) Peer-ReviewedAuthor(s): René Michael Hoet [2, 4]; Edward H Cohen [1, 4]; Rachel Baribault Kent [1]; Kristin Rookey [1]; Sonia Schoonbroodt [2]; Shannon Hogan [1]; Louise Rem [2]; Nicolas Frans [2]; Marc Daukandt [2]; Henk Pieters...
- 6From: Nature Biotechnology. (Vol. 23, Issue 3) Peer-ReviewedMany of biotech's greatest therapeutic successes are drugs used as adjuncts to conventional cancer therapies. Erythropoietin-α and granulocyte-macrophage colony stimulating factor are blockbusters that ameliorate the...
- 7From: Nature Biotechnology. (Vol. 23, Issue 3) Peer-ReviewedAuthor(s): Tom Jacobs [1] In biotech, most investors have favored drugmakers over companies using advances to create better protein catalysts--enzymes--and microorganisms. After all, drugs are high-profile, high-margin...
- 8From: Nature Biotechnology. (Vol. 23, Issue 3) Peer-ReviewedAuthor(s): Diego di Bernardo [1, 5]; Michael J Thompson [2, 5]; Timothy S Gardner [2, 5]; Sarah E Chobot [3]; Erin L Eastwood [3, 4]; Andrew P Wojtovich [3]; Sean J Elliott [3]; Scott E Schaus [3, 4]; James J Collins...
- 9From: Nature Biotechnology. (Vol. 23, Issue 3) Peer-ReviewedAuthor(s): Mark Ratner [1] Pleased with Sepracor's 2004 results and its anticipated launch in the first quarter of 2005 of one of biotech's rare mass-market drugs, investors have bid up the firm's stock to near...
- 10From: Nature Biotechnology. (Vol. 23, Issue 3) Peer-ReviewedAuthor(s): Yannick Rondelez [1]; Guillaume Tresset [1]; Kazuhito V Tabata [2, 3]; Hideyuki Arata [2]; Hiroyuki Fujita [2]; Shoji Takeuchi [2]; Hiroyuki Noji (corresponding author) [2] Precise understanding of...
- 11From: Nature Biotechnology. (Vol. 23, Issue 3) Peer-ReviewedNMR probe Designed for its Avance 400 NMR spectrometers, Bruker BioSpin's 400-MHz 5mm DCH CryoProbe improves the signal-to-noise ratio by 300% to 400% (compared to noncryogenically cooled probes) for high-resolution...
- 12From: Nature Biotechnology. (Vol. 23, Issue 3) Peer-ReviewedAuthor(s): Cormac Sheridan [1]; Alla Katsnelson [2] A new report, BioImpact , backed by European bioindustry lobbies, sets out the socioeconomic benefits of biotech-based therapies in ten disease areas but fails to...
- 13From: Nature Biotechnology. (Vol. 23, Issue 3) Peer-ReviewedAuthor(s): Mary Yaroshevsky-Glanville [1] The biotechnology workplace embodies diversity--it is a cultural melting pot with many perspectives and ideologies creating a rich foundation for innovation and creativity....
- 14From: Nature Biotechnology. (Vol. 23, Issue 3) Peer-ReviewedAuthor(s): Farren J Isaacs [1]; James J Collins [2] Most computer users, particularly those not technically inclined, are thankful for the recent advent of 'plug-and-play' devices that enable them to expand the...
- 15From: Nature Biotechnology. (Vol. 23, Issue 3) Peer-ReviewedAuthor(s): Jeffrey L. Fox [1] National Institutes of Health (NIH) director Elias Zerhouni announced sweeping reforms early in February that will halt consulting arrangements by NIH scientists and severely restrict...
- 16From: Nature Biotechnology. (Vol. 23, Issue 3) Peer-ReviewedAuthor(s): Yi Li [1]; Ruth Moysey [1]; Peter E Molloy [1]; Anne-Lise Vuidepot [1]; Tara Mahon [1]; Emma Baston [1]; Steven Dunn [1]; Nathaniel Liddy [1]; Jansen Jacob [1]; Bent K Jakobsen [1]; Jonathan M Boulter...
- 17From: Nature Biotechnology. (Vol. 23, Issue 3) Peer-ReviewedAuthor(s): Stephan Herrera [1] Nobody can say Patrick Moore doesn't have the courage of his convictions. When he was at Greenpeace, an organization he cofounded, he stood between seal pups and hammer-wielding thugs....
- 18From: Nature Biotechnology. (Vol. 23, Issue 3) Peer-ReviewedRecombinant cloning made sexy Recombinant DNA technologies based on in vitro nucleic acid manipulations using a battery of bacterial enzymes have been the cornerstone of molecular biology for the past several...
- 19From: Nature Biotechnology. (Vol. 23, Issue 3) Peer-ReviewedRecent patent applications in proteomics Table 1 Table: Recent patent applications in proteomics [see PDF for image] DOI: 10.1038/nbt0305-369...
- 20From: Nature Biotechnology. (Vol. 23, Issue 3) Peer-ReviewedAuthor(s): Stephan Herrera [1] To some, the scheduled opening this April of the new Center for Synthetic Biology (CSB) at the University of California (UC)-Berkeley provides yet more credence that the fledgling field...